Sugi Predict

Sugi Predict / Compounds / SCHEMBL29375953

SCHEMBL29375953

SCHEMBL29375953

CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)O)[C@@H](C)CC)C(C)C)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ TLR2 O60603 4/20 0.56
▸ RXFP1 Q9HBX9 2/20 0.56
▸ NPBWR1 P48145 7/20 0.55
▸ GLP1R P43220 2/20 0.53
▸ PTH1R Q03431 2/20 0.52
▸ MAGI3 Q5TCQ9 1/20 0.52
▸ CTSB P07858 1/20 0.51
▸ CTSK P43235 1/20 0.51
▸ BACE1 P56817 1/20 0.51
▸ GCGR P47871 1/20 0.51
▸ GIPR P48546 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350424 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL29373802 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL29606175 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL29412450 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL30043228 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL30636834 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL29606879 0.97 NPBWR1 (0.57) TLR2RXFP1NPBWR1GLP1RPTH1R
SCHEMBL29417894 0.95 NPBWR1 (0.59) TLR2RXFP1NPBWR1GLP1RCTSB
SCHEMBL29683439 0.90 NPBWR1 (0.59) NPBWR1GLP1RMAGI3CTSBCTSK
SCHEMBL31387893 0.89 GLP1R (0.65) NPBWR1GLP1RPTH1RGCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024196911-A1 ULTRACOMPACT PRECISION EDITING SYSTEMS AND USES THEREOF MAMMOTH BIOSCIENCES, INC. (US) 2024-09-26 — — WO claimed
US-20250346676-A1 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4 MOMENTA PHARMACEUTICALS INC (US) 2025-11-13 — — US disclosed
US-20250273634-A1 DISPLAY DEVICE Innolux Corporation (TW) 2025-08-28 — — US disclosed
US-12317724-B2 Display device Innolux Corporation (TW) 2025-05-27 — — US disclosed
WO-2025023056-A1 BASE STATION, COMMUNICATION DEVICE, CONTROL METHOD, AND PROGRAM キヤノン株式会社 2025-01-30 — — WO disclosed
US-12209267-B2 Microbial production of rotundone MANUS BIO INC. (US) 2025-01-28 — — US disclosed
US-20250011432-A1 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS MOMENTA PHARMACEUTICALS, INC. 2025-01-09 — — US disclosed
CN-118973332-A Display apparatus 群创光电股份有限公司 2024-11-15 — — CN disclosed
US-20240368574-A1 DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-11-07 — — US disclosed
WO-2024196911-A1 ULTRACOMPACT PRECISION EDITING SYSTEMS AND USES THEREOF MAMMOTH BIOSCIENCES, INC. (US) 2024-09-26 — — WO disclosed
US-11659755-B2 Display device Innolux Corporation (TW) 2023-05-23 — — US disclosed
US-11618908-B2 Microbial production of rotundone MANUS BIO INC. (US) 2023-04-04 — — US disclosed
US-20230065562-A1 DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-03-02 — — US disclosed
EP-3268014-B1 T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) 2022-09-21 — — EP disclosed
US-20220267460-A1 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS MOMENTA PHARMACEUTICALS, INC. 2022-08-25 — — US disclosed
CN-114648991-A Information processing system, control method thereof, storage medium storing control program thereof, and image processing apparatus 佳能株式会社 2022-06-21 — — CN disclosed
US-20220152100-A1 METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-05-19 — — US disclosed
US-20220125837-A1 METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-04-28 — — US disclosed
US-20220064298-A1 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4 MOMENTA PHARMACEUTICALS, INC. 2022-03-03 — — US disclosed
US-20220033499-A1 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS MOMENTA PHARMACEUTICALS, INC. 2022-02-03 — — US disclosed
Send feedback